These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 29395613)
1. Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS). Bartels-Velthuis AA; Visser E; Arends J; Pijnenborg GHM; Wunderink L; Jörg F; Veling W; Liemburg EJ; Castelein S; Knegtering H; Bruggeman R Schizophr Res; 2018 Jul; 197():281-287. PubMed ID: 29395613 [TBL] [Abstract][Full Text] [Related]
2. Persistent Low Rates of Treatment of Metabolic Risk Factors in People With Psychotic Disorders: A PHAMOUS Study. Bruins J; Pijnenborg GHM; van den Heuvel ER; Visser E; Corpeleijn E; Bartels-Velthuis AA; Bruggeman R; Jörg F J Clin Psychiatry; 2017; 78(8):1117-1125. PubMed ID: 28406264 [TBL] [Abstract][Full Text] [Related]
3. Exploring the use of Routine Outcome Monitoring in the treatment of patients with a psychotic disorder. Tasma M; Liemburg EJ; Knegtering H; Delespaul PAEG; Boonstra A; Castelein S Eur Psychiatry; 2017 May; 42():89-94. PubMed ID: 28314165 [TBL] [Abstract][Full Text] [Related]
4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
5. Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France. Arbus C; Clement JP; Bougerol T; Fremont P; Lancrenon S; Camus V Int Psychogeriatr; 2012 Mar; 24(3):496-502. PubMed ID: 21835072 [TBL] [Abstract][Full Text] [Related]
6. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Morgan VA; Waterreus A; Jablensky A; Mackinnon A; McGrath JJ; Carr V; Bush R; Castle D; Cohen M; Harvey C; Galletly C; Stain HJ; Neil AL; McGorry P; Hocking B; Shah S; Saw S Aust N Z J Psychiatry; 2012 Aug; 46(8):735-52. PubMed ID: 22696547 [TBL] [Abstract][Full Text] [Related]
7. Development of a health screening clinic. Millar HL Eur Psychiatry; 2010 Jun; 25 Suppl 2():S29-33. PubMed ID: 20620883 [TBL] [Abstract][Full Text] [Related]
9. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. van Winkel R; De Hert M; Van Eyck D; Hanssens L; Wampers M; Scheen A; Peuskens J J Clin Psychiatry; 2006 Oct; 67(10):1493-500. PubMed ID: 17107239 [TBL] [Abstract][Full Text] [Related]
10. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Helldin L; Kane JM; Karilampi U; Norlander T; Archer T Schizophr Res; 2007 Jul; 93(1-3):160-8. PubMed ID: 17395430 [TBL] [Abstract][Full Text] [Related]
11. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial. Storch Jakobsen A; Speyer H; Nørgaard HCB; Hjorthøj C; Krogh J; Mors O; Nordentoft M Schizophr Res; 2018 Sep; 199():96-102. PubMed ID: 29501386 [TBL] [Abstract][Full Text] [Related]
12. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668 [TBL] [Abstract][Full Text] [Related]
13. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Conley RR; Ascher-Svanum H; Zhu B; Faries DE; Kinon BJ Schizophr Res; 2007 Feb; 90(1-3):186-97. PubMed ID: 17110087 [TBL] [Abstract][Full Text] [Related]
14. A Retrospective Chart Review of Screening on the Prevalence of Metabolic Syndrome (MetS) in an Irish Community Mental Health Service. Cocoman AM; Gallagher D Issues Ment Health Nurs; 2019 Oct; 40(10):895-901. PubMed ID: 31295053 [TBL] [Abstract][Full Text] [Related]
15. Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder. Tasma M; Swart M; Wolters G; Liemburg E; Bruggeman R; Knegtering H; Castelein S BMC Psychiatry; 2016 Apr; 16():107. PubMed ID: 27091333 [TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care. Saloojee S; Burns JK; Motala AA Early Interv Psychiatry; 2018 Dec; 12(6):1137-1143. PubMed ID: 28402033 [TBL] [Abstract][Full Text] [Related]
17. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients. Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959 [TBL] [Abstract][Full Text] [Related]
18. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial. Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956 [TBL] [Abstract][Full Text] [Related]
20. Changes in physical and psychiatric health after a multidisciplinary lifestyle enhancing treatment for inpatients with severe mental illness: The MULTI study I. Deenik J; Tenback DE; Tak ECPM; Rutters F; Hendriksen IJM; van Harten PN Schizophr Res; 2019 Feb; 204():360-367. PubMed ID: 30055884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]